LAMISIL TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

TERBINAFINE (TERBINAFINE HYDROCHLORIDE)

থেকে পাওয়া:

NOVARTIS PHARMACEUTICALS CANADA INC

এটিসি কোড:

D01BA02

INN (আন্তর্জাতিক নাম):

TERBINAFINE

ডোজ:

250MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

14/28

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ALLYLAMINES

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0132855002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

1997-08-13

পণ্য বৈশিষ্ট্য

_LAMISIL_
_®_
_ (Terbinafine Hydrochloride) Product Monograph Page 1 of 58_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LAMISIL
®
Terbinafine Hydrochloride
Tablets, 250 mg, oral
Cream, 1% w/w (10 mg/g), topical
Spray solution, 1% w/w (10 mg/g), topical
Antifungal
ATC code: D01AE15
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, Quebec
H9S 1A9
www.novartis.ca
Date of Initial Authorization:
December 31, 1993
Date of Revision:
August 15, 2022
Control No. 261997
LAMISIL is a registered trademark.
_LAMISIL_
_®_
_ (Terbinafine Hydrochloride) Product Monograph _
_Page 2 of 58_
_ _
RECENT MAJOR LABEL CHANGES
None at the time of authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................5
2
CONTRAINDICATIONS
...................................................................................................5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................5
4
DOSAGE AND
ADMINISTRATION...................................................................................5
4.1
Dosing Considerations
.........................................................................................5
4.2
Recommended Dose and Dosage
Adjustment.......................................................5
4.4
Administration.............................................................